TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc. Phase 1.
TAK-733 is highly potent and selective MEK allosteric site inhibitor with IC50 of 3.2 nM. TAK-733 shows potent enzymatic and cell activity with an EC50 of 1.91酷彩网9 nM against ERK phosphorylation in cells. 
TAK-733 demonstrates broad antitumor activity in mouse xenograft models of human cancer including models of melanoma, colorectal, NSCLC, pancreatic and breast cancer. TAK-733 is well tolerated with pharmacokinetics and pharmacodynamics that support ondafa888comce-daily oral dosing in humans.  TAK-733 shows maximally efficacious doses at once daily orally doses of 10 mg/kg. 
 Qing Dong, et al. Bioorg Med Chem Lett, 2011, 21(5), 1315-1319.
 Fabrey R, et al. AACR Annual Meeting, 2012, Abs 3739.